ENGLEWOOD, Colo., Nov. 17, 2022 /PRNewswire/ — Ampio Pharmaceuticals received notification from NYSE American stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company’s common stock on the NYSE American.
Following the fifteen-to-one reverse stock split of the Company’s common stock, which became effective November 9, 2022, the NYSE Regulation staff determined that the Company’s common stock was trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. As such, the Exchange has withdrawn its delisting determination and will be lifting the trading suspension of the Company’s common stock on the NYSE American.
Ampio’s continued listing on the Exchange will be predicated on it demonstrating compliance with Section 1003(f)(v) of the NYSE American Company Guide through a period of at least December 23, 2022. The Company will update shareholders if and when it receives notification from the NYSE American that it has achieved compliance on this matter.
Ampio’s common stock will commence trading on the NYSE American on Tuesday, November 22, 2022 under the symbol “AMPE.”